---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-113237"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:18:31.661757+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharmaceuticals approves stock option award agreement forms under 2025 Equity Plan

## Summary
- Compensation Committee approved forms of Incentive and Non-Qualified Stock Option Award Agreements on Nov 14, 2025.
- Awards are governed by the 2025 Equity Incentive Plan; exercise price can be paid via cash, broker-assisted sales, or cashless exercise.
- Unvested options terminate upon employment cessation; vested options exercisable for up to 1 year after death/disability or 3 months after other termination.
- All awards subject to clawback policy as per Plan Section 16.6; forfeited shares subject to transfer powers.

## SEC filing metadata
- accession: 0001104659-25-113237
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925113237/0001104659-25-113237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925113237/tm2531454d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-113237
- JSON: https://secwatch.observer/filing/0001104659-25-113237.json
- Plain text: https://secwatch.observer/filing/0001104659-25-113237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.